Completed OBSERVATIONAL NCT01080027

Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR) (STAR)

An International, Multi Centre, Prospective, Observational Study of Safety, Tolerability and Adherence of Patients With Relapsing Remitting Multiple Sclerosis Administered Interferon Beta-1a (Rebif® New Formulation) in Real Life Settings

Sponsor: Merck A.B., Sweden

Conditions Multiple Sclerosis, Relapsing Remitting

Interventions Rebif® New Formulation

Updated 8 times since 2017 Last updated: Jul 30, 2014 Started: Oct 31, 2008 Primary completion: Jun 30, 2011 Completion: Jun 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Multiple Sclerosis, Relapsing Remitting and is currently completed. Merck A.B., Sweden leads this study, which shows 8 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jan 2019 — Jan 2021 [monthly]

Completed
Jun 2018 — Jan 2019 [monthly]

Completed

▶ Show 3 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Feb 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck A.B., Sweden
Merck A.E., Greece
Merck B.V., Netherlands
Merck KGaA, Darmstadt, Germany
Merck OY, Finland
Merck, S.A., Portugal

Data source: Merck KGaA, Darmstadt, Germany

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Thessaloniki, Greece